PMID- 19279518
OWN - NLM
STAT- MEDLINE
DCOM- 20090505
LR  - 20151119
IS  - 1541-8243 (Electronic)
IS  - 0038-4348 (Linking)
VI  - 102
IP  - 4
DP  - 2009 Apr
TI  - Effects of rosuvastatin and colestimide on metabolic parameters and urinary 
      monocyte chemoattractant protein-1 in type 2 diabetic patients with 
      hyperlipidemia.
PG  - 361-8
LID - 10.1097/SMJ.0b013e31819bd023 [doi]
AB  - BACKGROUND: Rosuvastatin, a strong statin, and colestimide, a new anion exchange 
      resin, are both clinically beneficial drugs for treatment of 
      hypercholesterolemia. The main purpose of the study was to compare the effects of 
      rosuvastatin and colestimide on metabolic parameters, adipokines, and markers of 
      oxidative stress and diabetic nephropathy in patients with type 2 diabetes 
      complicated by hyperlipidemia. DESIGN: A total of 40 patients with type 2 
      diabetes complicated by hyperlipidemia were recruited prospectively and 
      consecutively. The patients were assigned randomly in equal numbers to 
      rosuvastatin (2.5 mg/day) and colestimide (3.0 g/day) groups. Blood and urine 
      tests were performed at the beginning of the study and after 12 weeks. RESULTS: 
      Rosuvastatin significantly decreased the level of serum retinol-binding protein 
      (RBP)-4, an insulin-resistant adipokine, in a subgroup of patients with poor 
      glycemic control, in addition to exerting a strong low-density lipoprotein 
      (LDL-C)-lowering effect. Colestimide significantly decreased HbA1c, even in 
      patients treated with a sulfonylurea at a more than moderate dose, without 
      influencing insulin resistance or adiponectin (an insulin-sensitive adipokine) 
      and RBP4. Colestimide also significantly decreased the levels of urinary 
      8-iso-prostaglandin (PG) F2alpha (a marker of oxidative stress) and urinary 
      monocyte chemoattractant protein-1 (MCP-1) (a marker of diabetic nephropathy). 
      CONCLUSION: Our results show that rosuvastatin and colestimide exert different 
      beneficial effects in type 2 diabetic patients complicated by hyperlipidemia. 
      Therefore, concomitant use of these drugs may be useful for prevention of 
      progression of diabetic complications.
FAU - Takebayashi, Kohzo
AU  - Takebayashi K
AD  - Department of Internal Medicine, Dokkyo Medical University Koshigaya Hospital, 
      Koshigaya, Saitama, Japan. takeb@gmail.plala.or.jp
FAU - Suetsugu, Mariko
AU  - Suetsugu M
FAU - Matsumoto, Sachiko
AU  - Matsumoto S
FAU - Aso, Yoshimasa
AU  - Aso Y
FAU - Inukai, Toshihiko
AU  - Inukai T
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - South Med J
JT  - Southern medical journal
JID - 0404522
RN  - 0 (Chemokine CCL2)
RN  - 0 (Fluorobenzenes)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Imidazoles)
RN  - 0 (Peptide Fragments)
RN  - 0 (Pyrimidines)
RN  - 0 (Resins, Synthetic)
RN  - 0 (Retinol-Binding Proteins)
RN  - 0 (Sulfonamides)
RN  - 0 (colestimide)
RN  - 0 (monocyte chemoattractant protein 1 (66-77))
RN  - 08OOR508C0 (Epichlorohydrin)
RN  - 27415-26-5 (8-epi-prostaglandin F2alpha)
RN  - 83MVU38M7Q (Rosuvastatin Calcium)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - B7IN85G1HY (Dinoprost)
SB  - IM
MH  - C-Reactive Protein/metabolism
MH  - Chemokine CCL2/metabolism/*urine
MH  - Diabetes Mellitus, Type 2/*drug therapy/urine
MH  - Diabetic Nephropathies/urine
MH  - Dinoprost/analogs & derivatives/metabolism
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Epichlorohydrin/*therapeutic use
MH  - Female
MH  - Fluorobenzenes/*therapeutic use
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Hyperlipidemias/*drug therapy/urine
MH  - Imidazoles/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Oxidative Stress
MH  - Peptide Fragments/metabolism
MH  - Prospective Studies
MH  - Pyrimidines/*therapeutic use
MH  - Resins, Synthetic/*therapeutic use
MH  - Retinol-Binding Proteins/metabolism
MH  - Rosuvastatin Calcium
MH  - Sulfonamides/*therapeutic use
EDAT- 2009/03/13 09:00
MHDA- 2009/05/06 09:00
CRDT- 2009/03/13 09:00
PHST- 2009/03/13 09:00 [entrez]
PHST- 2009/03/13 09:00 [pubmed]
PHST- 2009/05/06 09:00 [medline]
AID - 10.1097/SMJ.0b013e31819bd023 [doi]
PST - ppublish
SO  - South Med J. 2009 Apr;102(4):361-8. doi: 10.1097/SMJ.0b013e31819bd023.